Although the therapeutic efficacy of chemo-PTT is more satisfactory than that of a single treatment alone, poor penetration and heterogeneous distribution of drugs in a tumor are other major obstacles that can cause an inevitable depth-dependent decline of treatment efficacy.13 Furthermore, in a multidrug-resistant (MDR) tumor, the efflux pumping of drugs by P-glycoprotein may compromise the therapeutic efficacy of a chemo-combined therapy,14 suggesting the need of a more effective approach to overcome resistance. This evidence concerns the gene ABCB1 and neoplasm.